表紙
市場調查報告書

肺炎球菌疫苗:全球治療藥市場預測與分析 (到2028年)

Pneumococcal Vaccines: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 932175
出版日期 內容資訊 英文 121 Pages
訂單完成後即時交付
價格
肺炎球菌疫苗:全球治療藥市場預測與分析 (到2028年) Pneumococcal Vaccines: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年03月30日內容資訊: 英文 121 Pages
簡介

全球肺炎球菌疫苗的市場規模,2018年是51億美元,預計2028年達62億美元,以約2%的年複合成長率擴大。市場為寡頭獨佔狀態,以及幾乎沒有未滿足需求,不過,由於價格上升和人口增加等的影響,新加入廠商仍有空間。

本報告提供全球主要9個國家(9MM:美國、法國、德國、義大利、西班牙、英國、日本、澳洲、韓國) 的肺炎球菌疫苗的市場相關分析,疾病概要和流行病學的背景,發病數量、患病人數趨勢預測 (今後10年份),臨床實驗的進展,已上市/臨床實驗中主要的調查治療藥,目前市場未滿足需求,主要企業的簡介,全球/主要國家的市場趨勢預測等。

第1章 目錄

第2章 肺炎球菌疫苗:概要

第3章 簡介

第4章 疾病概要

  • 病因與病理學
    • 病因
    • 病理生理學

第5章 流行病學

第6章 疫苗接種的推薦事項

第7章 競爭力的評估

  • 概況

第8章 未滿足需求和機會的評估

第9章 開發中產品的評估

第10章 現在、未來市場參與企業

第11章 市場未來展望

第12章 附錄

目錄
Product Code: GDHC185PIDR

Streptococcus pneumoniae (S. pneumoniae), a Gram-positive bacterial respiratory pathogen, is a leading cause of mortality and morbidity globally and is responsible for a large proportion of deaths due to infectious disease. In 2005, The World Health Organization (WHO) estimated 1.6 million deaths were caused by S. pneumoniae annually, including 0.7-1 million children under the age of 5 years. In Europe and the US, the annual incidence of pneumococcal disease ranges from 10 to 100 per 100,000 population. S. pneumoniae causes non-invasive infections such as acute otitis media, sinusitis, and bronchitis, as well as invasive infections such as pneumonia, meningitis, and septicemia. However, the introduction of pneumococcal conjugate and polysaccharide vaccines has significantly reduced burden associated with this disease, particularly in the pediatric and elderly segments.

While the pneumococcal vaccine market has been dominated by a very small number of players in most markets (Pfizer and Merck), and relatively little unmet need remains, the size of the market makes it a compelling proposition for players to consider entering. In 2018, GlobalData estimates the pneumococcal vaccines market to be $5.1B, with the best-selling vaccine globally, Prevnar (Prevenar outside the US) 13 accounting for $4.3B of these sales. Thus, while experts indicate that unmet need is modest, significant financial incentive remains for potential entrants. While GlobalData anticipates new pneumococcal vaccines to be launched in the forecast period, these agents only improve upon existing options, and will not change vaccination rates or vaccination recommendations, leaving pricing increases and population growth as the major influencers of the forecast.

Key Highlights

  • During the 10-year forecast period, three pipeline products that are on track to launch, driving a forecast growth in the 9MM from $5.1b in 2018 to $6.2b in 2028, which represents a CAGR of 2%.
  • The late stage pipeline for pneumococcal vaccines, targeting the unmet need of serogroup coverage, includes Merck's 15-valent pneumococcal vaccine V-114 and Pfizer's 20-valent vaccine 20vPnC.

Key Questions Answered

  • How will the pneumococcal vaccine market landscape in the 9MM (US, France, Germany, Italy, Spain, UK, Japan, Australia, South Korea) change from 2018-2028?
  • What are the most promising late-stage pipeline products for pneumococcal vaccination?
  • How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing immunization options?
  • What are the remaining unmet needs in pneumococcal immunization?
  • What drivers and barriers will affect pneumococcal vaccine sales in the 9MM over the forecast period?

Scope

  • Overview of pneumococcal disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline pneumococcal vaccines market revenue from 2018-2028. Annual cost of immunization and major pipeline product sales in this forecast period are included.
  • Key topics covered include current vaccination options, unmet needs and opportunities, and the drivers and barriers affecting pneumococcal vaccine sales in the 9MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global pneumococcal vaccine market. Insightful review of the key industry drivers, constraints, and challenges.
  • Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global pneumococcal vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the pneumococcal vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Pneumococcal Vaccines: Executive Summary

  • 2.1 Sales
  • 2.2 R&D Strategies
  • 2.3 Unmet Needs
  • 2.4 Remaining Opportunities for New Entrants
  • 2.5 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports
  • 3.3 Upcoming Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology

5 Epidemiology

6 Immunization Recommendations

7 Competitive Assessment

  • 7.1 Overview

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

10 Current and Future Players

11 Market Outlook

12 Appendix

List of Tables

  • Table 1: Pneumococcal Vaccines Key Metrics in the 9MM
  • Table 2: Risk Factors and Comorbidities for Invasive Pneumococcal Disease
  • Table 3: 7MM, Pediatric Pneumococcal Vaccination Rate Trends (%)
  • Table 4: 6MM, Elderly Pneumococcal Vaccination Rate Trends (%)
  • Table 5: 3GM, Pediatric Pneumococcal Vaccination Rate Trends (%)
  • Table 6: 3GM, Elderly Pneumococcal Vaccination Rate Trends (%)
  • Table 7: Vaccination Guidelines for Pneumococcal Disease
  • Table 8: Leading Pneumococcal Vaccines
  • Table 9: Pfizer's Pneumococcal Vaccine Portfolio Assessment, 2020
  • Table 10: Merck's Pneumococcal Vaccine Portfolio Assessment, 2020
  • Table 11: Pneumococcal Vaccine Market - Global Drivers and Barriers, 2018-2028
  • Table 12: Key Events Impacting Sales for Pneumococcal Vaccines in the US, 2018-2028
  • Table 13: Pneumococcal Vaccines Market - Drivers and Barriers in the US, 2018-2028
  • Table 14: Key Events Impacting Sales for Pneumococcal Vaccines in the 5EU, 2018-2028
  • Table 15: Pneumococcal Vaccines Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 16: Key Events Impacting Sales for Pneumococcal Vaccines in Japan, 2018-2028
  • Table 17: Pneumococcal Vaccines Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 18: Key Events Impacting Sales for Pneumococcal Vaccines in Australia, 2018-2028
  • Table 19: Pneumococcal Vaccines Market - Global Drivers and Barriers in Australia, 2018-2028
  • Table 20: Key Events Impacting Sales for Pneumococcal Vaccines in South Korea, 2018-2028
  • Table 21: Pneumococcal Vaccines Market - Global Drivers and Barriers in South Korea, 2018-2028
  • Table 22: Key Historical and Projected Launch Dates for Pneumococcal Vaccines
  • Table 23: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: Global Sales Forecast by Country for Pneumococcal Vaccines in 2018 and 2028
  • Figure 2: Analysis of the Company Portfolio Gap in Pneumococcal Vaccines During the Forecast Period
  • Figure 3: Competitive Assessment of the Late-Stage Pneumococcal Vaccines that GlobalData Expects to Be Licensed for the Treatment of Pneumococcal Vaccines During the Forecast Period
  • Figure 4: A Schematic Diagram of the Virulence Factors of S. pneumoniae
  • Figure 5: The Life Cycle of S. pneumoniae and the Pathogenesis of Pneumococcal Disease
  • Figure 6: 7MM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008*2028
  • Figure 7: 3GM, Diagnosed Incidence of IPD, Both Sexes, All Ages, 2008-2028
  • Figure 8: 7MM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
  • Figure 9: 6MM, Sources Used for the Pneumococcal Vaccinated Elderly Population
  • Figure 10: 7MM, Sources Used for the Diagnosed Incident Cases of IPD
  • Figure 11: 3GM, Sources Used for the Pneumococcal Vaccinated Pediatric Population
  • Figure 12: 3GM, Sources Used for the Pneumococcal Vaccinated Elderly Population
  • Figure 13: 3GM, Sources Used for the Diagnosed Incident Cases of IPD
  • Figure 14: 7MM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
  • Figure 15: 3GM, Pneumococcal Vaccinated Pediatric Population, Both Sexes, 2018
  • Figure 16: 6MM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
  • Figure 17: 3GM, Pneumococcal Vaccinated Elderly Population, Both Sexes, 2018
  • Figure 18: 7MM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
  • Figure 19: 3GM, Diagnosed Incident Cases of IPD, Both Sexes, All Ages, 2018
  • Figure 20: 7MM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, 2018
  • Figure 21: 3GM, Age-Specific Diagnosed Incident Cases of IPD, Men and Women, N, 2018
  • Figure 22: Pneumococcal Vaccination Schedule for the 9MM
  • Figure 23: Unmet Needs and Opportunities in Pneumococcal Vaccines
  • Figure 24: Overview of the Development Pipeline for Pneumococcal Vaccines
  • Figure 25: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Pneumococcal Vaccination in the 9MM During the Forecast Period
  • Figure 26: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Pneumococcal Disease During the Forecast Period
  • Figure 27: Analysis of the Company Portfolio Gap in Pneumococcal Vaccination During the Forecast Period
  • Figure 28: Global (9MM) Sales Forecast by Country for Pneumococcal Vaccines in 2018 and 2028
  • Figure 29: Sales Forecast by Class for Pneumococcal Vaccines in the US in 2018 and 2028
  • Figure 30: Sales Forecast by Class for Pneumococcal Vaccines in the 5EU in 2018 and 2028
  • Figure 31: Sales Forecast by Class for Pneumococcal Vaccines in Japan in 2018 and 2028
  • Figure 32: Sales Forecast by Class for Pneumococcal Vaccines in Australia in 2018 and 2028
  • Figure 33: Sales Forecast by Class for Pneumococcal Vaccines in South Korea in 2018 and 2028